机构地区:[1]安徽中医药大学附属太和县中医院药事科,阜阳236600 [2]安徽中医药大学附属太和县中医院肝病科,阜阳236600
出 处:《中国药物应用与监测》2024年第4期372-375,共4页Chinese Journal of Drug Application and Monitoring
摘 要:目的 探讨异甘草酸镁注射液对肝恶性肿瘤患者的疗效及其对肝功能、炎症因子的影响。方法 纳入2022年1月至2024年1月安徽中医药大学附属太和县中医院住院部收治的98例肝恶性肿瘤患者,以随机数字表法分为两组,每组49例,患者均接受肝动脉化疗栓塞术(transcatheter arterial chemoembolization,TACE)治疗,对照组术后应用还原型谷胱甘肽注射液治疗,观察组术后采取还原型谷胱甘肽注射液联合异甘草酸镁注射液治疗,各治疗10 d,比较两组的临床疗效、肝损伤发生率、不良反应、肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)等血清炎症因子水平、甲胎蛋白(AFP)。结果 观察组与对照组的总有效率分别为71.43%和63.27%,差异无统计学意义(χ^(2)=0.742,P>0.05);观察组肝损伤发生率(28.57%)低于对照组(59.18%),差异具有统计学意义(χ^(2)=9.324,P<0.05);观察组与对照组的不良反应发生率分别为2.04%和4.08%,差异无统计学意义(χ^(2)=0.344,P>0.05);治疗后,观察组TNF-α及IL-6水平分别为(41.25±4.23)μg·m L^(-1)、(35.49±5.23)μg·m L^(-1),均低于对照组[分别为(69.23±6.62)μg·m L^(-1)、(57.73±4.23)μg·m L^(-1)],差异具有统计学意义(t=24.931、48.908,均P<0.05);治疗后,观察组AFP水平为(77.63±6.93) pg·m L^(-1),低于对照组(122.65±9.54) pg·m L^(-1),差异具有统计学意义(t=26.726,P<0.05)。结论 异甘草酸镁注射液可较好保护TACE治疗的肝恶性肿瘤患者的肝功能,还可一定程度抑制肿瘤,提升治疗效果,且治疗安全可靠,利于患者病情好转。Objective To investigate the efficacy of magnesium isoglycyrrhizinate injection in treatment of liver malignant tumor and its effect on liver function and inflammatory factors.Methods A total of 98 patients with liver malignant tumor admitted to Taihe County Hospital of Traditional Chinese Medicine affiliated to Anhui University of Chinese Medicine from January 2022 to January 2024 were enrolled in this study and divided into two groups by random number table method.All patients received transcatheter arterial chemoembolization(TACE)treatment.The patients in the control group(n=49)were treated with reduced glutathione injection after surgery while those in the observation group(n=49)with reduced glutathione injection and magnesium isoglycyrrhizinate injection after surgery for 10 days.The clinical curative effect,the incidence of liver injury,adverse reactions,serum levels of tumor necrosis factor Alpha(TNF-α),interleukin-6(IL-6)and AFP were compared between the two groups.Results The total effective rate was 71.43%in the observation group and 63.27%in the control(x^(2)=0.742,P>0.05),showing no statistical significance.The incidence of liver injury in the observation group(28.57%)was lower than that in the control(59.18%)(x^(2)=9.324,P<0.05).The adverse reaction rate was 2.04%in the observation group and 4.08%in the control(x^(2)=0.344,P>0.05),demonstrating no statistical significance.After treatment,the serum levels of TNF-αand IL-6 in the observation group were(41.25±4.23)μg·mL^(-1) and(35.49±5.23)μg·mL^(-1),respectively,which were lower than those of(69.23±6.62)μg·mL^(-1) and(57.73±4.23)μg·mL^(-1) in the control(t=24.931,48.908,both P<0.05).The AFP level in the observation group was(77.63±6.93)pg·mL^(-1),which was lower than that of(122.65±9.54)pg·mL^(-1) in the control(t=26.726,P<0.05).Conclusion Magnesium isoglycyrrhizinate injection can better protect the liver function of patients with liver malignant tumor treated by TACE,inhibit the tumor to a certain extent and improve the therapeutic
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...